Cellectis (France) Performance
| ALCLS Stock | EUR 3.57 0.08 2.29% |
On a scale of 0 to 100, Cellectis holds a performance score of 5. The firm shows a Beta (market volatility) of 1.5, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cellectis will likely underperform. Please check Cellectis' downside variance, and the relationship between the sortino ratio and accumulation distribution , to make a quick decision on whether Cellectis' price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cellectis are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Cellectis reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 241.1 M | |
| Total Cashflows From Investing Activities | 7.3 M |
Cellectis |
Cellectis Relative Risk vs. Return Landscape
If you would invest 311.00 in Cellectis on October 22, 2025 and sell it today you would earn a total of 46.00 from holding Cellectis or generate 14.79% return on investment over 90 days. Cellectis is generating 0.3608% of daily returns and assumes 5.2088% volatility on return distribution over the 90 days horizon. Simply put, 46% of stocks are less volatile than Cellectis, and 93% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Cellectis Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cellectis' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cellectis, and traders can use it to determine the average amount a Cellectis' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0693
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ALCLS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.21 actual daily | 46 54% of assets are more volatile |
Expected Return
| 0.36 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Cellectis is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cellectis by adding it to a well-diversified portfolio.
Cellectis Fundamentals Growth
Cellectis Stock prices reflect investors' perceptions of the future prospects and financial health of Cellectis, and Cellectis fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cellectis Stock performance.
| Return On Equity | -0.56 | |||
| Return On Asset | -0.24 | |||
| Operating Margin | (6.01) % | |||
| Current Valuation | 78.42 M | |||
| Shares Outstanding | 55.59 M | |||
| Price To Earning | (14.84) X | |||
| Price To Book | 0.77 X | |||
| Price To Sales | 4.34 X | |||
| Revenue | 57.29 M | |||
| EBITDA | (92.29 M) | |||
| Cash And Equivalents | 47.91 M | |||
| Cash Per Share | 9.93 X | |||
| Total Debt | 91.56 M | |||
| Debt To Equity | 8.20 % | |||
| Book Value Per Share | 3.00 X | |||
| Cash Flow From Operations | (104.56 M) | |||
| Earnings Per Share | (2.13) X | |||
| Total Asset | 382.08 M | |||
| Retained Earnings | (194 M) | |||
| Current Asset | 305 M | |||
| Current Liabilities | 66 M | |||
About Cellectis Performance
Assessing Cellectis' fundamental ratios provides investors with valuable insights into Cellectis' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Cellectis is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is based in Paris, France. CELLECTIS operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 161 people.Things to note about Cellectis performance evaluation
Checking the ongoing alerts about Cellectis for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cellectis help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cellectis had very high historical volatility over the last 90 days | |
| The company reported the revenue of 57.29 M. Net Loss for the year was (114.2 M) with profit before overhead, payroll, taxes, and interest of 34.18 M. | |
| Cellectis has accumulated about 47.91 M in cash with (104.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Cellectis' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cellectis' stock is overvalued or undervalued compared to its peers.
- Examining Cellectis' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cellectis' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cellectis' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cellectis' stock. These opinions can provide insight into Cellectis' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.